Cargando…

Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients’ characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Saglik, Imran, Turkkan, Alparslan, Turan, Cansu, Kara, Ates, Akalin, Halis, Ener, Beyza, Sahin, Ahmet, Yesil, Edanur, Celebi, Solmaz, Kazak, Esra, Heper, Yasemin, Yilmaz, Emel, Korkmaz, Muhammet Furkan, Ture, Esra, Hacimustafaoglu, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924986/
https://www.ncbi.nlm.nih.gov/pubmed/35308741
http://dx.doi.org/10.7759/cureus.22195
_version_ 1784669972079837184
author Saglik, Imran
Turkkan, Alparslan
Turan, Cansu
Kara, Ates
Akalin, Halis
Ener, Beyza
Sahin, Ahmet
Yesil, Edanur
Celebi, Solmaz
Kazak, Esra
Heper, Yasemin
Yilmaz, Emel
Korkmaz, Muhammet Furkan
Ture, Esra
Hacimustafaoglu, Mustafa
author_facet Saglik, Imran
Turkkan, Alparslan
Turan, Cansu
Kara, Ates
Akalin, Halis
Ener, Beyza
Sahin, Ahmet
Yesil, Edanur
Celebi, Solmaz
Kazak, Esra
Heper, Yasemin
Yilmaz, Emel
Korkmaz, Muhammet Furkan
Ture, Esra
Hacimustafaoglu, Mustafa
author_sort Saglik, Imran
collection PubMed
description Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients’ characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical specimens. Methods This prospective study investigated SARS-CoV-2-specific antibodies among 43 adults and 34 children at a mean of 12 weeks after the onset of COVID-19 symptoms using six serological assays and compared their performance. We used two Euroimmun (Euroimmun, Luebeck, Germany), two automated Roche Elecsys (Basel, Switzerland), and two rapid immuno-chromatographic Ecotest (Matrix Diagnostics, Assure Tech. (Hangzhou) Co., L, China) assays to investigate SARS-CoV-2 antibodies. Results The findings showed that the Roche Elecsys anti-S total test yielded the best positivity/sensitivity (children 94.1% and adults 93.0%; p = 0.877) while five immunoglobulin IgG targeting assays had similar positivity/sensitivity between children (88.2% to 94.1%) and adults (88.4% to 93.0%) (p > 0.05). Although IgM positivity was relatively low (p < 0.001), it was found in the majority of our pediatric and adult patients (67.6% and 86.0%, respectively; p = 0.098). SARS-CoV-2 S IgG titers were found to be higher among males in pediatric and adult groups compared to females (p = 0.027 and p = 0.041, respectively). Furthermore, we observed significantly higher antibody titers among pneumonia patients (p = 0.001). Conclusion Overall, we concluded SARS-CoV-2 antibody persistence over an average of 12 weeks after the onset of COVID-19 symptoms. While automated Roche Elecsys total antibody assays yielded the best sensitivity (> 90%) and five assays targeting IgG had acceptable performance. Patients with pneumonia and males have higher antibody titers. The effect of antibody persistence on re-infections should be monitored in longitudinal studies.
format Online
Article
Text
id pubmed-8924986
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89249862022-03-18 Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 Saglik, Imran Turkkan, Alparslan Turan, Cansu Kara, Ates Akalin, Halis Ener, Beyza Sahin, Ahmet Yesil, Edanur Celebi, Solmaz Kazak, Esra Heper, Yasemin Yilmaz, Emel Korkmaz, Muhammet Furkan Ture, Esra Hacimustafaoglu, Mustafa Cureus Infectious Disease Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients’ characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical specimens. Methods This prospective study investigated SARS-CoV-2-specific antibodies among 43 adults and 34 children at a mean of 12 weeks after the onset of COVID-19 symptoms using six serological assays and compared their performance. We used two Euroimmun (Euroimmun, Luebeck, Germany), two automated Roche Elecsys (Basel, Switzerland), and two rapid immuno-chromatographic Ecotest (Matrix Diagnostics, Assure Tech. (Hangzhou) Co., L, China) assays to investigate SARS-CoV-2 antibodies. Results The findings showed that the Roche Elecsys anti-S total test yielded the best positivity/sensitivity (children 94.1% and adults 93.0%; p = 0.877) while five immunoglobulin IgG targeting assays had similar positivity/sensitivity between children (88.2% to 94.1%) and adults (88.4% to 93.0%) (p > 0.05). Although IgM positivity was relatively low (p < 0.001), it was found in the majority of our pediatric and adult patients (67.6% and 86.0%, respectively; p = 0.098). SARS-CoV-2 S IgG titers were found to be higher among males in pediatric and adult groups compared to females (p = 0.027 and p = 0.041, respectively). Furthermore, we observed significantly higher antibody titers among pneumonia patients (p = 0.001). Conclusion Overall, we concluded SARS-CoV-2 antibody persistence over an average of 12 weeks after the onset of COVID-19 symptoms. While automated Roche Elecsys total antibody assays yielded the best sensitivity (> 90%) and five assays targeting IgG had acceptable performance. Patients with pneumonia and males have higher antibody titers. The effect of antibody persistence on re-infections should be monitored in longitudinal studies. Cureus 2022-02-14 /pmc/articles/PMC8924986/ /pubmed/35308741 http://dx.doi.org/10.7759/cureus.22195 Text en Copyright © 2022, Saglik et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Infectious Disease
Saglik, Imran
Turkkan, Alparslan
Turan, Cansu
Kara, Ates
Akalin, Halis
Ener, Beyza
Sahin, Ahmet
Yesil, Edanur
Celebi, Solmaz
Kazak, Esra
Heper, Yasemin
Yilmaz, Emel
Korkmaz, Muhammet Furkan
Ture, Esra
Hacimustafaoglu, Mustafa
Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
title Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
title_full Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
title_fullStr Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
title_full_unstemmed Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
title_short Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
title_sort comparison of sars-cov-2 antibodies and six immunoassays in pediatric and adult patients 12 weeks after covid-19
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924986/
https://www.ncbi.nlm.nih.gov/pubmed/35308741
http://dx.doi.org/10.7759/cureus.22195
work_keys_str_mv AT saglikimran comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT turkkanalparslan comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT turancansu comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT karaates comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT akalinhalis comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT enerbeyza comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT sahinahmet comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT yesiledanur comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT celebisolmaz comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT kazakesra comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT heperyasemin comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT yilmazemel comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT korkmazmuhammetfurkan comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT tureesra comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19
AT hacimustafaoglumustafa comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19